Leiters and Mobius Therapeutics have entered into a national sales and marketing agreement for the only FDA-approved mitomycin C formulation with an ophthalmic indication, according to a press release.
Mitosol (mitomycin for solution 0.2 mg/vial) is available as part of an ophthalmic use kit, which also includes accessories for safe and compliant acquisition, storage and handling, the release said.
The agreement allows Mobius to supply Mitosol in order to minimize supply disruption.
“We are excited to partner with Mobius Therapeutics to ensure our ophthalmic customers have access to the

Full Story →

Leiters and Mobius Therapeutics have entered into a national sales and marketing agreement for the only FDA-approved mitomycin C formulation with an ophthalmic indication, according to a press release.
Mitosol (mitomycin for solution 0.2 mg/vial) is available as part of an ophthalmic use kit, which also includes accessories for safe and compliant acquisition, storage and handling, the release said.
The agreement allows Mobius to supply Mitosol in order to minimize supply disruption.
“We are excited to partner with Mobius Therapeutics to ensure our ophthalmic customers have access to the

Full Story →